Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance about €1.4 billion ($1.48 billion) in bonds ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

Grifols ends acquisition talks with Brookfield over valuation concerns, highlights strong revenue growth and financial ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...

Canadian investment fund Brookfield said Wednesday it has dropped its bid for Spanish pharmaceutical firm Grifols following ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...

The Board of Directors of Grifols (GRFS) announced the termination of discussions with Brookfield Capital Partners UK regarding a ...

(Bloomberg) -- The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance bonds due next year and extend a revolving credit line — together about €1.4 billion ($1.48 ...

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition. This decision follows the company’s November 19 ...